UBS sticks with Buy on Cerebras at $155 as customer list widens beyond OpenAI

UBS is still in Cerebras Systems’ corner. The bank has kept its Buy rating and its $155 price target on the AI chipmaker, pointing to a customer roster that is finally growing beyond a single giant name.

The vote of confidence comes with a caveat attached. UBS also flagged the risks tied to how quickly Cerebras can ramp its OpenAI business, which remains the company’s biggest relationship by a wide margin.

A Buy rating with a smaller number attached

The $155 target is not new. UBS analyst Timothy Arcuri set it in a report issued around November 13, 2026, when he cut his target from $250 while reaffirming the Buy call.

The timing of that cut was notable. It landed a day after Cerebras (NASDAQ: CBRS) posted third-quarter 2026 results on November 12 that beat expectations.

The company reported Q3 GAAP revenue of $210.8 million. On an adjusted basis, revenue came in at $230.9 million, also ahead of estimates.

Cerebras also lifted its full-year 2026 core revenue guidance to a range of $940–960 million.

Shares rose in after-hours trading following the report. Still, the stock remains below its IPO levels.

Why diversification is the headline story

Arcuri’s central argument is that Cerebras is spreading its bets. Its customer base now includes major cloud providers such as AWS, Oracle and Microsoft.

The Microsoft piece is the newest. Cerebras signed a cloud agreement with the software giant in October 2026, and revenue from that deal is expected to start contributing in the first quarter of 2027.

Then there is OpenAI. Cerebras holds a multi-year deal with the ChatGPT maker valued at over $20 billion, covering up to 750 MW of inference capacity and running through 2028.

The OpenAI problem, politely stated

OpenAI accounts for a substantial majority of Cerebras’ forecasted obligations, according to the research underpinning UBS’s view.

Execution is the specific worry. Infrastructure constraints have been affecting delivery timelines on major deals, which means signed contracts do not automatically turn into recognized revenue on schedule.

Background: a big IPO and a bumpy aftermath

Cerebras went public on May 14, 2026, pricing shares at $185 each. The offering raised approximately $6.38 billion.

Since that debut, the company has worked to build out its partner ecosystem. The additions of AWS, Oracle and Microsoft are the most visible results of that effort.

The share price has not followed the same upward script. Trading below the IPO level means many early buyers are sitting on paper losses, despite the company beating estimates and raising guidance.

UBS’s own target also sits below that $185 IPO price.

What this means for investors

The key thing to watch is customer concentration. Each quarter where Microsoft, AWS and Oracle grow as a share of revenue reduces the company’s dependence on OpenAI.

The Microsoft revenue start in Q1 2027 is the next concrete checkpoint. If that contribution shows up on time, it strengthens the diversification case UBS is making.

Delivery timelines are the other variable. Infrastructure constraints have already pressured deal schedules, and investors will want evidence that Cerebras can convert its large commitments into revenue at the pace it has promised.